Certara (NASDAQ:CERT) Issues FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of 0.450-0.470 for the period, compared to the consensus earnings per share estimate of 0.390. The company issued revenue guidance of $415.0 million-$420.0 million, compared to the consensus revenue estimate of $418.4 million.

Certara Price Performance

Shares of CERT opened at $8.99 on Friday. Certara has a twelve month low of $8.02 and a twelve month high of $15.69. The company has a market capitalization of $1.43 billion, a P/E ratio of 128.49 and a beta of 1.46. The firm has a 50 day moving average of $9.78 and a 200 day moving average of $10.71. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last issued its earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The business had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. During the same period last year, the business posted $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, equities research analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of recent analyst reports. Craig Hallum initiated coverage on Certara in a research report on Monday, September 29th. They issued a “buy” rating and a $16.00 target price for the company. KeyCorp increased their price objective on shares of Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. BMO Capital Markets initiated coverage on shares of Certara in a research report on Thursday, November 13th. They issued a “market perform” rating and a $9.00 target price for the company. Rothschild & Co Redburn initiated coverage on shares of Certara in a research note on Friday, November 21st. They set a “buy” rating and a $10.00 target price for the company. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Certara in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Certara currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.91.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CIBC Bancorp USA Inc. purchased a new position in Certara during the third quarter valued at approximately $2,844,000. Morningstar Investment Management LLC bought a new stake in shares of Certara during the 3rd quarter valued at $1,598,000. Wasatch Advisors LP lifted its stake in shares of Certara by 28.6% during the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock valued at $212,608,000 after buying an additional 3,865,455 shares in the last quarter. Parkman Healthcare Partners LLC boosted its holdings in Certara by 10.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 551,850 shares of the company’s stock worth $6,744,000 after buying an additional 51,850 shares during the period. Finally, Gotham Asset Management LLC increased its stake in Certara by 44.5% in the 3rd quarter. Gotham Asset Management LLC now owns 471,122 shares of the company’s stock worth $5,757,000 after buying an additional 145,062 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.